Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,381 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A, Ling J, Kenkare-Mitra SR, Lum BL. Frohna P, et al. Among authors: wolf j. J Clin Pharmacol. 2006 Mar;46(3):282-90. doi: 10.1177/0091270005284193. J Clin Pharmacol. 2006. PMID: 16490804 Clinical Trial.
Effects of smoking on the pharmacokinetics of erlotinib.
Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ. Hamilton M, et al. Among authors: wolf jl. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71. doi: 10.1158/1078-0432.CCR-05-2235. Clin Cancer Res. 2006. PMID: 16609030 Clinical Trial.
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA, Schwartz G, Beeram M, Hidalgo M, Mita MM, Wolf J, Nadler P, Rowinsky EK. Patnaik A, et al. Among authors: wolf j. Clin Cancer Res. 2006 Dec 15;12(24):7406-13. doi: 10.1158/1078-0432.CCR-06-1886. Clin Cancer Res. 2006. PMID: 17189413 Clinical Trial.
Influence of Mutations and N-Glycosylation Sites in the Receptor-Binding Domain (RBD) and the Membrane Protein of SARS-CoV-2 Variants of Concern on Antibody Binding in ELISA.
Schwarze M, Volke D, Rojas Echeverri JC, Schick R, Lakowa N, Grünewald T, Wolf J, Borte S, Scholz M, Krizsan A, Hoffmann R. Schwarze M, et al. Among authors: wolf j. Biology (Basel). 2024 Mar 23;13(4):207. doi: 10.3390/biology13040207. Biology (Basel). 2024. PMID: 38666819 Free PMC article.
4,381 results